Archives
-
Pirfenidone as a Benchmark for Fibrosis Biology
2026-09-29
A translational framework for using Pirfenidone as a clinically anchored antifibrotic benchmark in pulmonary fibrosis research, while distinguishing its broad inflammatory and matrix effects from the PBK/SRC-associated mechanisms reported for worenine.
-
Machine-Learning Discovery of Senolytics
2026-09-28
The reference study shows that cost-effective machine-learning models trained only on published screening data can identify senolytic candidates despite small and heterogeneous datasets. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin as compounds with senolytic activity, offering a practical framework for phenotype-first drug discovery.
-
KNUCKLES Controls Floral Meristem Termination
2026-09-28
In Arabidopsis, KNUCKLES contributes to floral meristem termination not only by repressing stem-cell maintenance genes, but also by regulating auxin distribution and cytokinin activity. The study links these hormone effects to repression of PIN1 and IPT7 and H3K27me3 deposition, extending the molecular explanation for how floral determinacy is timed.
-
HMGB1 Proteomics for Early Diabetic Nephropathy
2026-09-27
This study combined serum quantitative proteomics with expression-pattern clustering and network analysis to identify candidate biomarkers associated with diabetic nephropathy progression. HMGB1 was prioritized and supported by high-glucose cell and animal experiments, but it remains a candidate for further clinical validation rather than an established diagnostic test.
-
ICG001: Selective Wnt/β-Catenin Pathway Inhibition
2026-09-26
ICG001 is a Wnt/β-catenin pathway inhibitor that selectively targets the β-catenin–CBP interaction, providing a tool for studying Wnt signaling modulation. Product information reports activity in cancer and fibrosis models, but those experimental findings do not establish clinical efficacy.
-
Triazole ALDH2 Activators Protect Against Myocardial I/R
2026-09-25
A 2025 study used molecular simulation and structure-guided optimization to develop triazole activators of aldehyde dehydrogenase 2 (ALDH2), seeking stronger activity and better water solubility than earlier compounds. In a mouse myocardial ischemia–reperfusion model, its lead compound, Z17, improved cardiac-function measures and reduced infarct and injury-marker outcomes; these preclinical findings support further investigation, not a clinical treatment claim.
-
MARCH5 Controls Mitochondria-Derived Pre-Peroxisomes
2026-09-25
Zheng et al. identify mitochondria-localized MARCH5 as a regulator of PEX3-containing vesicle budding, an early step in mitochondria-contributed peroxisome biogenesis. Their findings distinguish this vesicle population from other mitochondria-derived vesicles and point to roles for both the MARCH5 RING and C-terminal domains in maintaining peroxisome homeostasis.
-
Wortmannin as a Probe of PI3K-Dependent Viral Entry
2026-09-24
Wortmannin is a potent PI3K inhibitor that can help researchers test whether PI3K-sensitive processes contribute to viral entry. This article examines the reasoning and assay controls behind a grass carp reovirus study—and explains why inhibitor sensitivity is evidence to interpret, not a complete mechanism by itself.
-
Honokiol Workflows for NF-κB and T-Cell Studies
2026-09-24
Use Honokiol to probe inflammatory signaling and oxidative stress alongside—not as a stand-in for—the CD28–ARS2–PKM mechanism recently linked to CD8+ T-cell metabolic flexibility. This workflow pairs dose-finding with pathway, splicing, metabolic, and viability readouts to help separate compound effects from activation biology.
-
β-NMN: Designing Stronger Metabolic Studies
2026-09-23
Explore how beta-Nicotinamide mononucleotide (β-NMN) can help researchers test the links between NAD+ availability, SIRT3 signaling, and metabolic disease. This article focuses on experimental logic—how to distinguish a change in NAD+ from evidence for a specific cardiac fibrosis mechanism.
-
HyperScribe Co-transcription mRNA Synthesis Kit Plus
2026-09-23
Build translationally competent, ARCA-capped mRNA with a defined template-encoded poly(A) tail for in vitro translation, RNA vaccine development, and functional RNA studies. This workflow emphasizes template architecture, practical reaction controls, and troubleshooting so researchers can move from sequence design to interpretable assay results.
-
CRISPR DNA Repair Pathway Choice by Drug Repurposing
2026-09-22
Macak, Kanis, and Riesenberg report a large approved-drug screen that links chemical perturbations to NHEJ, MMEJ, and HDR outcomes after CRISPR-induced DNA breaks. The study also identifies ESR2 and AOX1 as regulatory nodes and shows that ESR2 silencing can enhance HDR when combined with NHEJ inhibition, creating a framework for genome editing optimization and synthetic-lethality research.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-09-22
The reference study develops a localized tumor suppressor replacement strategy by packaging chemically modified CDKN1A/p21 mRNA in lipid nanoparticles for intravesical delivery. Across cellular, tissue, distribution, and orthotopic mouse experiments, transient p21 restoration inhibited cell-cycle progression, increased DNA-damage signaling, promoted apoptosis, and reduced bladder tumor growth.
-
CDK8 Inhibition in Osteoarthritis: Study Insights
2026-09-21
A 2026 Bone Research study identifies CDK8/19 inhibition as a way to modulate chondrocyte hypertrophy, inflammatory signaling, metabolism, and endochondral ossification in osteoarthritis. Its integrated cell, human tissue, transcriptomic, and STR/Ort mouse experiments suggest a multiprocess disease-modifying strategy, while also defining important limits for translating the findings to chemical-probe workflows.
-
Tamoxifen Workflows for CreER and Tumor Biology
2026-09-21
Build more interpretable CreER-mediated gene knockout and tumor-biology assays with Tamoxifen, from controlled dissolution through recombination and mitochondrial-iron readouts. This workflow also shows how to separate genetic effects from Tamoxifen-driven estrogen-receptor, autophagy, apoptosis, or protein-kinase signaling.